1. Signaling Pathways
  2. GPCR/G Protein
  3. LPL Receptor
  4. LPAR3 Isoform

LPAR3

Lysophosphatidic acid receptor 3 (LPAR3) is a G protein-coupled receptor that mediates calcium signaling in epithelial and neuronal cells[1][2]. Mechanistically, LPAR3 activation stimulates intracellular calcium flux via Gq/PLC pathways, regulating chloride secretion at the ocular surface and modulating erythropoietic processes in hematopoietic stem cells[1][2]. In vivo, LPAR3 knockout models in zebrafish exhibit behavioral alterations, including disrupted circadian locomotor activity, reduced aggression, and impaired memory, demonstrating its involvement in neurobehavioral regulation[2]. In disease models, LPAR3 contributes to ocular surface homeostasis, including Cl^- transport in corneal epithelial cells, suggesting potential roles in dry eye and neuropathic pain[1]. Compared with related LPA receptors such as LPAR1 and LPAR5, LPAR3 exhibits distinct tissue expression patterns in ocular, hematopoietic, and neural cells, as well as selective coupling to calcium-dependent signaling rather than exclusively PI3K/AKT or cAMP pathways[1][2][3]. Pharmacologically, LPAR3-selective agonists like 2S-OMPT enhance calcium-dependent chloride secretion in human corneal epithelial cells, providing experimental tools for studying epithelial transport and ocular surface disease mechanisms[1]. Dual LPAR1/LPAR3 antagonists can mitigate LPC/LPA-induced visceral hypersensitivity, highlighting LPAR3 as a target for pain modulation[3]. Collectively, these findings define LPAR3 as a versatile receptor with functional specificity in calcium signaling, neurobehavior, epithelial transport, and sensory modulation.

LPAR3 Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-15706
    H2L 5765834
    Antagonist 98.66%
    H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA1, LPA3, and LPA5, with IC50s of 94, 752, and 463 nM respectively.
  • HY-178845
    Decyl phosphate
    Modulator
    Decyl phosphate is a selective LPA2 agonist (EC50: 1.8 μM) and LPA1/LPA3 antagonist. Decyl phosphate can be used in the research of blood disorders.
  • HY-148291
    BrP-LPA sodium
    Antagonist
    BrP-LPA sodium is a pan-opposite agent for lysophosphatidic acid (LPA). It has antagonistic activity against LPA1 (IC50 = 4520 nM), LPA2 (IC50 = 468 nM), LPA3, and LPA4. BrP-LPA sodium also has partial agonistic activity for LPA5, with its EC50 being 1282 nM. BrP-LPA sodium has ATX inhibitory activity. BrP-LPA sodium effectively inhibits the migration and invasion of breast cancer cells. BrP-LPA sodium achieves tumor regression and anti-angiogenesis in mice breast cancer xenograft model. BrP-LPA sodium can be used for the study of breast cancer.
  • HY-W725737
    BrP-LPA
    Antagonist
    BrP-LPA is a LPA antagonist/ATX inhibitor. BrP-LPA shows pan-antagonist activity towards LPA1-4 GPCRs. BrP-LPA decreases blood vessel density. BrP-LPA dose-dependently inhibits Lysophosphatidic acid-induced head-dip counts. BrP-LPA exhibits anticancer activity against breast cancer, colon cancer, and lung cancer. BrP-LPA inhibits anxiety-like behavior.